Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XL114 |
| Synonyms | |
| Therapy Description |
XL114 (AUR104) binds to and inhibits fatty acid-binding protein 5 (FABP5), resulting in decreased MALT1 pathway signaling and potentially leading to decreased tumor cell proliferation and antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1266). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XL114 | XL-114|XL 114|AUR 104|AUR104|AUR-104 | XL114 (AUR104) binds to and inhibits fatty acid-binding protein 5 (FABP5), resulting in decreased MALT1 pathway signaling and potentially leading to decreased tumor cell proliferation and antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1266). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05144347 | Phase I | XL114 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Terminated | USA | 0 |